Retatrutide Dosing & Reconstitution Guide

The administration of Retatrutide is designed for subcutaneous delivery, specifically utilizing formulations employed in clinical trials. Research has indicated that dosing occurs on a weekly basis, with the Phase 2 trials evaluating a range of doses: 1 mg, 4 mg, 8 mg, and 12 mg, all administered once weekly. The optimal therapeutic dose is currently under investigation in ongoing Phase 3 trials. The duration of treatment in the Phase 2 study spanned 48 weeks, with participants receiving doses on the same day each week to maintain consistency in pharmacokinetics.

The titration of Retatrutide is structured to facilitate a gradual increase in dosage, promoting safety and tolerability. Initial doses during the first four weeks range from 1 to 2 mg weekly, allowing for patient acclimatization. Following this initiation phase, the dose is escalated to 4 mg weekly from weeks five to eight. Subsequently, from weeks nine to twelve, the dosage increases to 8 mg weekly. For maintenance therapy beyond week twelve, doses between 8 mg and 12 mg weekly are employed, reflecting a tailored approach based on individual patient response and tolerability.

For optimal preservation, Retatrutide should be stored under specific conditions. The lyophilized form of the peptide is best maintained at a temperature of −20 °C (−4 °F), ensuring stability until reconstitution. Once reconstituted, Retatrutide should be kept refrigerated at temperatures ranging from 2 to 8 °C (35.6 to 46.4 °F). It is important to note that the shelf life of the reconstituted solution is limited to 28 days, necessitating careful management to prevent degradation and loss of potency.

Subcutaneous administration of Retatrutide can be performed at various anatomical sites, with the abdomen and thigh being the most commonly utilized areas. These sites provide adequate subcutaneous tissue for injection, facilitating absorption of the peptide. Researchers should consider rotating injection sites to minimize discomfort and potential tissue irritation, ensuring a more comfortable experience for subjects involved in clinical studies.

Safety assessments of Retatrutide reveal a spectrum of gastrointestinal side effects that are dose-dependent, with incidence rates ranging from 13% to 63% across various dosage groups. Commonly reported effects include nausea, vomiting, diarrhea, and constipation, which are typically mild to moderate in severity. Notably, dose-dependent increases in heart rate have been observed, peaking at 24 weeks before declining. As for contraindications, these are not yet firmly established due to the investigational nature of the product. However, potential contraindications may align with those of the GLP-1 receptor agonist class, including personal or family history of medullary thyroid carcinoma and multiple endocrine neoplasia type 2 (MEN2). Additionally, caution is advised regarding use during pregnancy.